Furaprevir

Summary

Furaprevir (CHEMBL4297647) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including hepatitis c virus infection and chronic hepatitis c virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 897 Da · C47H56N6O10S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297647
Name	Furaprevir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	51037069
Molecular formula	C47H56N6O10S
Molecular weight	897
InChIKey	GZRNOYTVBWWFLJ-NTPALUMKSA-N

SMILES: CC(C)OC1=CC=C(C=C1)C2=NC3=C(C(=N2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6/C=C\CCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)NS(=O)(=O)C8(CC8)C)OC9=CC=CC=C93

IUPAC name: cyclopentyl N-[(1S,4R,6S,7Z,14S,18R)-4-[(1-methylcyclopropyl)sulfonylcarbamoyl]-2,15-dioxo-18-[[2-(4-propan-2-yloxyphenyl)-[1]benzofuro[3,2-d]pyrimidin-4-yl]oxy]-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-14-yl]carbamate

Also known as: Furaprevir, Tg-2349, TG-2349, FURAPREVIR

Patent coverage: 10 distinct patent families (23 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 18 (78%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047
chronic hepatitis C virus infection	2	MONDO:0005354	EFO:0004220

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE1	2
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04155515	PHASE3	COMPLETED	A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
NCT02340962	PHASE2	COMPLETED	Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
NCT01523990	PHASE1	COMPLETED	A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients
NCT03610880	PHASE1	COMPLETED	To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).